A gene expression-based screening assay using chimeric mice with humanized hepatocytes revealed that letrozole has a modifying effect on fibrosis-related gene expression in the hepatocytes, including YAP, CTGF, TGF-β, and ...
Nov 8, 2022
1
2
Results of a new study by neuroscientists at the University of Massachusetts Amherst and the University of Toronto suggest that a new treatment approach is needed—and how this may be possible—to address adverse effects ...
Dec 24, 2018
1
37
U.S. regulators have approved a new drug as an initial treatment for postmenopausal women with a type of advanced breast cancer.
Mar 13, 2017
0
0
Federal health regulators on Tuesday approved a highly anticipated medicine from Pfizer Inc. to treat postmenopausal women with a certain type of advanced breast cancer who have not already taken other drugs.
Feb 3, 2015
1
3
The drug letrozole results in higher birth rates in women with polycystic ovary syndrome (PCOS) than the current preferred infertility treatment drug, according to a nationwide study led by Penn State College of Medicine ...
Jul 9, 2014
0
1
Drugmaker Pfizer Inc. said Monday that a midstage study of its experimental drug for advanced breast cancer, palbociclib, met the main goal.
Feb 3, 2014
0
0
A biomarker reflecting expression levels of two genes in tumor tissue may be able to predict which women treated for estrogen-receptor (ER)-positive breast cancer should receive a second estrogen-blocking medication after ...
Jun 29, 2013
0
0
Pfizer Inc. says its experimental pill for advanced, often deadly breast cancer has been designated as a breakthrough therapy by the Food and Drug Administration.
Apr 10, 2013
0
0
(HealthDay)—An experimental cancer drug may delay the progression of some advanced breast cancers, while a double dose of an existing cancer drug could help women live longer, according to separate studies reported Wednesday.
Dec 5, 2012
0
0
(HealthDay)—For women with estrogen receptor (ER)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer, the investigational agent PD 0332991 plus letrozole improves progression-free survival versus ...
Dec 5, 2012
0
0
